Investigating the effectiveness of adding Clonidine and Gabapentin to Buprenorphine during detoxification of children and adolescents with Opioid Use Disorders

Not Applicable

• Conditions: Opioid Use Disorders.; Opioid abuse; F11.1

• Registration Number: IRCT20110411006168N4
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Diagnosis of opioid use disorder based on DSM-5 by a child and adolescent psychiatrist
age 5-18 years old

Exclusion Criteria

Allergy to buprenorphine or clonidine or gabapentin.
Chronic or inflammatory diseases (heart, lung, liver, kidney or neurological diseases such as epilepsy).
Serious psychiatric illnesses such as schizophrenia and other psychotic disorders, acute phase of bipolar disorder and moderate to severe mental disability.
Dissatisfaction of the patient's parent or Legal guardian to continue the plan.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Withdrawal symptoms according to psychiatrist examination and patient report. Timepoint: days 1 to 14. Method of measurement: Clinical opioid withdrawal scale and subjective opioid withdrawal scale.

Secondary Outcome Measures

Name	Time	Method
Drug side effects. Timepoint: day 1 to 14. Method of measurement: Checklist of drug side effects.